Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
Pradaxa ® (dabigatran etexilate) drives Boehringer Ingelheim ' s innovation promise in cardiovascular diseases (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New Pradaxa ® data to be presented at the ESC Congress 2014
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Benefits of Pradaxa ® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New data on safety and efficacy of Pradaxa ® in treatment of acute deep vein thrombosis and pulmonary embolism
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa ® than with warfarin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
FDA Approves Praxbind ® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Safety and efficacy of Pradaxa ® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa ® on kidney function over time compared to warfarin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Efficacy and Safety Profile of Pradaxa ® (dabigatran etexilate) Repeatedly Confirmed
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New Pradaxa ® data to be presented at the ESC Congress 2014
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Extensive experience in clinical practice and expanding research programme support use of Pradaxa ® for clot prevention
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Pradaxa ® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New Pradaxa ® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ® (dabigatran etexilate) specific investigational antidote
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim launches RE-COVERY DVT/PE ™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
